Toujeo label initial u.s. approval 2015?

What year was Toujeo first approved in the U.S.?

Toujeo (insulin glargine injection, 300 units/mL) received its initial U.S. approval in 2015 [1].

When did Toujeo come to market after approval?

FDA approval is the start of the product’s U.S. availability under that label; the specific marketing start date (how soon after approval it was sold) isn’t provided in the cited source [1].

Which FDA review label does this refer to (brand name vs. biosimilar/generic)?

The 2015 approval is for the branded product Toujeo (not a biosimilar or generic), as reflected in the FDA product labeling timeline [1].

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206201